Lower urinary tract dysfunction (LUTD) is present in the vast majority of patients with an underlying neurological disorder. Although LUTD can be an enormous burden for the patients and thus greatly affecting the quality of life, only few effective treatment options are currently available. Additionally, these treatments aim at ameliorating urinary symptoms rather than curing LUTD. Several promising therapies for neurogenic LUTD (NLUTD) have been developed in pre-clinical studies and are now being tested in clinical trials. These include neuromodulatory therapies, early application of botulinum toxin, bacteriophages for recurrent urinary tract infection, stem-cells, and regenerative therapies. These new experimental treatments have the potential to revolutionize patient management. Nonetheless, the therapies presented in this chapter are in very early stages of clinical development and it might therefore take many years before they can be broadly implemented.